跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
NCL-1
首页
药物
NCL-1
NCL-1
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
Mitochondrial targeted RNA expression system and use thereof
US 8883755 B2
申请人: UNIV PITTSBURGH
优先权: 2013
US
3 件公开
PEPTIDE C ALPHA-AMIDES, METHODS FOR PREPARING SAME AND USES THEREOF AS PRECURSORS OF PEPTIDE C ALPHA- THIOESTERS FOR PROTEIN SYNTHESIS
US 2015018519 A1
申请人: CENTRE NAT RECH SCIENT
优先权: 2012
US
Manganese and zinc metal complexes taking alocasia amazonica alkali as ligand as well as synthesis method and application of manganese and zinc metal complexes
CN 104844635 A
申请人: UNIV GUANGXI NORMAL
优先权: 2015
CN
一种用于二泛素合成的新型辅基连接臂及其合成方法和应用
CN 109705007 B
申请人: 合肥工业大学
优先权: 2019
CN
一种用于治疗肺癌的药物组合物及其应用
CN 111617073 B
申请人: 黑龙江中医药大学
优先权: 2020
CN
吡唑啉酮衍生物、注射剂及其用途
CN 112375072 B
申请人: 上海长征富民金山制药有限公司
优先权: 2020
CN
AS1411 oligonucleotide composite ruthenium complex nanoprobe as well as preparation method and application thereof
CN 115057891 A
申请人: UNIV GUANGDONG PHARM
优先权: 2022
CN
Antibody modified by lysine lactic acid at 477 < th > site of nucleolin as well as preparation method and application of antibody
CN 116804055 A
申请人: CHINESE PEOPLE'S LIBERATION ARMY AIR FORCE MILITARY MEDICAL UNIV
优先权: 2023
CN
Method for enhancing colon cancer resisting function of Vdelta1gamma deltaT cells
CN 120267818 A
申请人: HENAN CANCER HOSPITAL
优先权: 2025
CN
Application of substance aiming at VDAC1 target spot in preparation of product and medicine for preventing and treating diseases caused by RSV
CN 121401419 A
申请人: UNIV GUIZHOU MEDICAL
优先权: 2025
CN
第 1 / 2 页
上一页
下一页
药物
反馈